Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
Pouyiourou M, Kraft BN, Wohlfromm T, Stahl M, Kubuschok B, Löffler H, Hacker UT, Hübner G, Weiss L, Bitzer M, Ernst T, Schütt P, Hielscher T, Delorme S, Kirchner M, Kazdal D, Ball M, Kluck K, Stenzinger A, Bochtler T, Krämer A. Pouyiourou M, et al. Among authors: delorme s. Nat Commun. 2023 Oct 24;14(1):6761. doi: 10.1038/s41467-023-42400-5. Nat Commun. 2023. PMID: 37875494 Free PMC article. Clinical Trial.
Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation.
Mosebach J, Shah S, Delorme S, Hielscher T, Goldschmidt H, Schlemmer HP, Schönland S, Hegenbart U, Hillengass J. Mosebach J, et al. Among authors: delorme s. Haematologica. 2018 Feb;103(2):336-343. doi: 10.3324/haematol.2017.176073. Epub 2017 Dec 7. Haematologica. 2018. PMID: 29217779 Free PMC article.
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.
Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Raab MS, Hillengass M, Wagner B, Jauch A, Hose D, Weber MA, Delorme S, Goldschmidt H, Hillengass J. Mai EK, et al. Among authors: delorme s. Haematologica. 2015 Jun;100(6):818-25. doi: 10.3324/haematol.2015.124115. Epub 2015 Mar 20. Haematologica. 2015. PMID: 25795721 Free PMC article.
Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology.
Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Hillengass M, Wagner B, Hose D, Raab MS, Jauch A, Delorme S, Goldschmidt H, Weber MA, Hillengass J. Mai EK, et al. Among authors: delorme s. Eur Radiol. 2016 Nov;26(11):3939-3948. doi: 10.1007/s00330-015-4195-0. Epub 2016 Jan 15. Eur Radiol. 2016. PMID: 26767378
Susceptibility-weighted imaging in malignant melanoma brain metastasis.
Schwarz D, Niederle T, Münch P, Hielscher T, Hassel JC, Schlemmer HP, Platten M, Winkler F, Wick W, Heiland S, Delorme S, Bendszus M, Bäumer P, Breckwoldt MO. Schwarz D, et al. Among authors: delorme s. J Magn Reson Imaging. 2019 Oct;50(4):1251-1259. doi: 10.1002/jmri.26692. Epub 2019 Feb 21. J Magn Reson Imaging. 2019. PMID: 30793419
Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage.
Wennmann M, Goldschmidt H, Mosebach J, Hielscher T, Bäuerle T, Komljenovic D, McCarthy PL, Merz M, Schlemmer HP, Raab MS, Sauer S, Delorme S, Hillengass J. Wennmann M, et al. Among authors: delorme s. Br J Haematol. 2022 Oct;199(1):65-75. doi: 10.1111/bjh.18232. Epub 2022 May 24. Br J Haematol. 2022. PMID: 35608264
Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma.
Hillengass J, Ayyaz S, Kilk K, Weber MA, Hielscher T, Shah R, Hose D, Delorme S, Goldschmidt H, Neben K. Hillengass J, et al. Among authors: delorme s. Haematologica. 2012 Nov;97(11):1757-60. doi: 10.3324/haematol.2012.065359. Epub 2012 Jun 11. Haematologica. 2012. PMID: 22689673 Free PMC article. Clinical Trial.
371 results